These therapies can improve treatment efficacy and reduce side effects by upregulating Phosphatase and Tensin Homolog (PTEN) and suppressing Programmed death-ligand 1 (PD-L1) in tumor cells, thereby boosting immune responses and recruiting NK and T cells to the tumor microenvironment [55,56]. The gene discussed is PTEN; the disease is neoplasm.